Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 38Neoplasm Metastasis 16Leukemia, Myeloid, Acute 13Skin Neoplasms 10Kidney Neoplasms 10Leukemia 9Carcinoma, Renal Cell 9Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 6Lymphoma, Non-Hodgkin 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Congenital Abnormalities 4Neuroblastoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Recurrence 2Papillomavirus Infections 2Pancreatic Neoplasms 2Lymphoma, Mantle-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1

Interventions

Cisplatin 27Cetuximab 17Radiotherapy 14Carboplatin 14pembrolizumab 11Paclitaxel 11Drug Therapy 8Radiotherapy, Intensity-Modulated 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7Radiation 6Docetaxel 5130-nm albumin-bound paclitaxel 5Panitumumab 4Chemoradiotherapy 3Capecitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Afatinib 3selinexor 2figitumumab 2Restraint, Physical 2Radiosurgery 2Methotrexate 2Lapatinib 2Everolimus 2Esophagectomy 2Cyclophosphamide 2zalutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Squamous Cell × Interleukin-2 × Clear all
NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡